| Outcome Measures: |
Primary: HbA1c at 4 Months, Primary end point of the study is the HbA1c level in response to canagliflozin alone, liraglutide or canagliflozin with liraglutide., Approximately 4 months|Fasting Plasma Glucose (FPG) at 4 Months, Values will be presented as the mean + (Standard Deviation) SD. The difference in HGP and all secondary endpoints at study end versus baseline will be calculated and compared between each active treatment group with ANOVA., Baseline to Approximately 4 months | Secondary: Body Mass Index (BMI) at 4 Months, A measure of BMI at 4 months to examine effects of combination therapy with liraglutide plus canagliflozin., Approximately 4 months | Other: Change in Matsuda Index of Insulin Sensitivity, Insulin Secretion, and Beta Cell Function During Oral Glucose Tolerance Test (OGTT), Values will be presented as the mean + SD. The Matsuda Index is a novel assessment of insulin sensitivity that is simple to calculate and provides a reasonable approximation of whole-body insulin sensitivity from the OGTT. The index is calculated from plasma glucose (mg/dl) and insulin (mIU/l) concentrations in both fasting state and post-OGTT. The index value obtained is compared to normal physiologic values to assess insulin sensitivity or resistance. The higher the number, the more insulin sensitive and the lower the number the more insulin resistant the subjects are. Insulin secretion will be measured from plasma C-peptide concentration during the OGTT and the Mari Model will be used to measure beta cell glucose sensitivity, Change from Baseline to Approximately 4 months|Change in Free Plasma Insulin at the End of the Study From Baseline Value, Values will be presented as the mean + SD. The difference in HGP and all secondary endpoints at study end versus baseline will be calculated and compared between each active treatment group with ANOVA., At Approximately 4 months|Change in Plasma Glucagon Concentration at the End of the Study Compared to Baseline, Values will be presented as the mean + SD. The difference in HGP and all secondary endpoints at study end versus baseline will be calculated and compared between each active treatment group with ANOVA., Approximately 4 months|Change in Total Body Weight at Study End Compared to Baseline, Values will be presented as the mean + SD. The difference in HGP and all secondary endpoints at study end versus baseline will be calculated and compared between each active treatment group with ANOVA. The difference between baseline and study end will represent the change in body weight due to change in hepatic, visceral and abdominal subcutaneous fat., Approximately 4 months|Change in 24-hour Blood Pressure at Study End Compared to Baseline., Values will be presented as the mean + SD. The difference in HGP and all secondary endpoints at study end versus baseline will be calculated and compared between each active treatment group with ANOVA., Approximately 4 months
|
